Vaccines

MIT researchers have developed new technology that allows vaccines to be directly inserted into the lymph nodes to target two of the most common mutations in the KRAS gene, which cause roughly one third of all cancers, reports Jaimie Seaton for Scientific American. “The team modified the small vaccine components to include a fatty acid, which enables the vaccine to effectively hitch a ride on albumin, a common protein found throughout the body,” explains Seaton. “Albumin serves as a molecular shuttle bus, with pockets on its surface where fatty acids can bind to it.”

Researchers at MIT have developed a mobile vaccine printer capable of printing a vaccine onto a patch of microneedles that can be absorbed into the skin without injection, reports Sandra Tsing for NPR. “These printed vaccines could be used in areas that are unable to refrigerate traditional vaccines,” explains Tsing.

Institute Prof. Bob Langer speaks with Curiosity podcast hosts Immad Akhynd and Raj Suri about his work in the field of biotechnology, delving into how he has co-founded 40 companies. “I wanted to get out and do some good in the world,” says Langer. “That's where patents come in and that's where companies come in. And I think the challenge of the company is very different because you have what I call a platform technology.”

Principal Research Scientist Ana Jaklenec speaks with CBC host Bob McDonald about her work developing a mobile vaccine printer. The device “can be very important in certain scenarios when you’re trying to bring the ability to vaccinate in areas that might not have the right infrastructure to make vaccines or even to administer vaccines,” says Jaklenec, “so I think the portability is key here.” 

Researchers at MIT have developed a mobile printer that could create microneedle patches for mRNA vaccine delivery. “These "microneedle patches" offer a range of advantages over traditional jabs in the arm, including that they can be self-administered, are relatively painless, could be more palatable to the vaccine-hesitant and can be stored at room temperature for long periods of time,” writes Daniel Lawler for Agence France-Presse.

Research scientist Ana Jaklenec spoke with Jonathan Grinstein at Genetic Engineering & Biotechnology News about a new microneedle patch printer she and her colleagues have developed that may one day enable on-demand vaccine manufacturing. “The idea was that you could, in an emergency situation, deploy some of these printers and locally vaccinate the population to prevent the global spread of infection,” says Jaklenec.

Using an artificial intelligence system, researchers at MIT and elsewhere have developed a new Covid-19 vaccine that could be effective against current and future strains, reports Gwen Egan for Boston.com. “The vaccine differs from others currently on the market due to the portion of the virus being targeted,” writes Egan.  

Boston Globe reporter Hiawatha Bray writes that MIT researchers have used an AI system to identify a potential new Covid-19 vaccine that may be effective against both current and future variants of the virus. “The new vaccine targets a portion of the COVID virus that is much less prone to evolve,” writes Bray. “That could potentially make it effective against many different versions of the virus, eliminating the need for routine booster shots.”

MIT researchers have developed a new approach to vaccines that uses “a machine learning twist [that] could put an end to boosters and seasonal variant shots,” reports Devin Coldewey for TechCrunch.

Vaxxes, a Cambridge startup based on research conducted at MIT and Tufts University, is working toward “the creation of a vaccine that’s easy to use, doesn’t require refrigeration, and releases slowly in the skin for a stronger immune response,” reports Ryan Cross for The Boston Globe.

Institute Professor Robert Langer has been honored as one of the recipients of this year’s Balzan Prize for his “pioneering research and advances in mRNA vaccines and tissue engineering,” the Associated Press reports. Langer has paved the way “for breakthroughs in the controlled release of macromolecules with many medical applications,” the Balzan Foundation noted in its citation.

Doctoral research specialist Morteza Sarmadi speaks with Emily Henderson from News Medical Life Sciences about his work with Prof. Robert Langer and research scientist Ana Jaklenec in developing microparticles that are able to deliver self-boosting vaccines. “We believe this technique can significantly reduce the need to visit a healthcare provider to receive booster shots, a major challenge in remote areas without sophisticated healthcare resources,” says Sarmadi.

Scientists at MIT are developing a self-boosting vaccine that can provide multiple doses of a vaccine via a single injection, reports Darko Manevski for Newsweek. The technology “could be particularly useful for administering childhood vaccinations in regions where people do not have regular access to medical care,” writes Manevski.

MIT scientists are developing self-boosting vaccine technology that could allow people to receive all of their vaccine doses in one shot, reports The Economist. This technology “would be a game-changer, not only for future pandemics but also for vaccination programs in remote regions where it is harder to deliver boosters,” The Economist notes.

Writing for The Boston Globe, Prof. Edward Scolnick and La Jolla Institute for Immunology Prof. Erica Ollmann Saphire share their insights on the future and potential challenges in developing a universal Covid-19 vaccine. “Success will require two principles that the world has not yet sufficiently grasped in fighting this virus: a focus on the long term over the short term, and a sustainable structure and support for collaboration,” write Scolnick and Saphire.